Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ASND Ascendis Pharma A/S

Closed 07-10 16:00:00 EDT

270.45

-4.98

-1.81%

盘后270.45

+0.000.00%

19:14 EDT

High276.91	Low267.85	Vol375.37K
Open275.43	D1 Closing275.43	Amplitude3.29%
Mkt Cap16.76B	Tradable Cap16.59B	Total Shares61.98M
T/O101.52M	T/O Rate0.61%	Tradable Shares61.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ASND","market":"US","secType":"STK","nameCN":"Ascendis Pharma A/S","latestPrice":270.45,"timestamp":1783713600000,"preClose":275.43,"halted":0,"volume":375370,"hourTrading":{"tag":"盘后","latestPrice":270.45,"preClose":270.45,"latestTime":"19:14 EDT","volume":11519,"amount":3115315.39,"timestamp":1783725292216,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01808081908288864,"floatShares":61326699,"shares":61977400,"eps":8.646,"marketStatus":"Closed","change":-4.98,"latestTime":"07-10 16:00:00 EDT","open":275.43,"high":276.91,"low":267.85,"amount":101515430.66260001,"amplitude":0.032894,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":8.646,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":5,"adr":1,"adrRate":1,"listingDate":1422421200000,"exchange":"NASDAQ","adjPreClose":275.43,"preHourTrading":{"tag":"盘前","latestPrice":278,"preClose":275.43,"latestTime":"08:03 EDT","volume":14,"amount":3899.45038,"timestamp":1783685012143,"change":2.57,"changeRate":0.009331,"amplitude":0.020114},"postHourTrading":{"tag":"盘后","latestPrice":270.45,"preClose":270.45,"latestTime":"19:14 EDT","volume":11519,"amount":3115315.39,"timestamp":1783725292216,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.598871,"impliedVol":0.4598,"impliedVolPercentile":0.3984},"requestUrl":"/m/hq/s/ASND","defaultTab":"news","newsList":[{"id":"2650921821","title":"Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2650921821","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650921821?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:04","pubTimestamp":1783598683,"startTime":"0","endTime":"0","summary":"Ascendis Pharma's (ASND) strong stock performance will likely continue after a more than 30% return in the past few weeks, Wedbush analysts said in a Thursday note.The analysts said that recent 5-year","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4585","LU0320765992.SGD","LU0109394709.USD","MEDI","LU0889565916.HKD","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650592946","title":"Wedbush Raises Price Target on Ascendis Pharma to $327 From $273, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2650592946","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650592946?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:48","pubTimestamp":1783597728,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) has an average rating of buy and mean price target of $295.07, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MEDI","BK4585","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650925623","title":"Ascendis Pharma A/s : Wedbush Raises Target Price to $327 from $273","url":"https://stock-news.laohu8.com/highlight/detail?id=2650925623","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650925623?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:40","pubTimestamp":1783593634,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nFWN43B0NR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","MEDI","BK4139","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650914471","title":"Ascendis Pharma Releases Week 104 Approach Trial Radiographic Data Presentation on Transcon CNP in Achondroplasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2650914471","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650914471?lang=en_us&edition=fundamental","pubTime":"2026-07-09 08:25","pubTimestamp":1783556734,"startTime":"0","endTime":"0","summary":"Ascendis Pharma releases Week 104 ApproaCH trial radiographic data presentation on TransCon CNP in achondroplasiaAscendis Pharma released week-104 radiographic results from the pivotal ApproaCH trial ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL7cRy31:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","BK4585","MEDI","BK4139","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649992507","title":"European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2649992507","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649992507?lang=en_us&edition=fundamental","pubTime":"2026-07-08 23:09","pubTimestamp":1783523397,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking lower late Wednesday morning, falling 1.11% to 1,892.74 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by petroleum refiner Equinor  and oil and gas company Eni , which rose 2.4% each. They were followed by accommodations booking site trivago  and pharmaceutical company Ascendis Pharma , which gained 1.7% and 0.7%, respectively.The decliners from continental Europe were led by lender Banco Santander  and software company SAP , which fell 5.1% and 3.7%, respectively. They were followed by internet advertising company Criteo  and biopharmaceutical company Cellectis , which declined 3.5% and 1.1%, respectively.The gainers from the UK were led by oil and gas company BP  and biotech company Autolus Therapeutics , which advanced 1.7% and 1.6%, respectively. They were followed by telecommunications company Vodafone Group  and educational publisher Pearson , which each gained 0.5%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRTO","SLN","EPV","USE","BK4111","BPH","ASND","VOD","PXE","DIG","BK4009","TRIB","DBC","ERX","BP","TRVG","E","CLLS","VDE","WPP","IEUR","GSIB","IEO","DBE","BK4139","DRLL","GUSH","EQNR","AFG","IXC","AKTX","LU0006061336.USD","BK4201","BK4107","BK4521","WPP.AU","FTXN","BK4585","SAN","XES","WTIU","DRIP","PSO","AUTL","LU0162691827.USD","SAN.AU","MEDI","PXJ","SAP","BK4204"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649961600","title":"Barclays Remains a Buy on Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649961600","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649961600?lang=en_us&edition=fundamental","pubTime":"2026-07-08 16:47","pubTimestamp":1783500430,"startTime":"0","endTime":"0","summary":"Barclays analyst Eliana Merle maintained a Buy rating on Ascendis Pharma today and set a price target of $345.00. According to TipRanks, Merle is a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MEDI","BK4585","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648202693","title":"Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2648202693","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648202693?lang=en_us&edition=fundamental","pubTime":"2026-07-04 07:30","pubTimestamp":1783121414,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (NasdaqGS:ASND) is back in focus after new Week 104 radiographic data from its pivotal ApproaCH trial of once weekly TransCon CNP in children with achondroplasia highlighted continued improvements in lower limb alignment and growth.\nSee our latest analysis for Ascendis Pharma.\nThe fresh Week 104 ApproaCH data and February FDA approval sit alongside steady price momentum, with Ascendis Pharma posting a 1-day share price return of 2.51% and a 30-day share price return of 26.62%...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/ascendis-pharma-asnd-could-be-7-undervalued-following-fresh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/ascendis-pharma-asnd-could-be-7-undervalued-following-fresh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LU0889565916.HKD","BK4585","ASND","MEDI","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648774542","title":"14 Value Stocks of Companies Primed for Rapid Growth Through 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2648774542","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648774542?lang=en_us&edition=fundamental","pubTime":"2026-07-02 00:10","pubTimestamp":1782922200,"startTime":"0","endTime":"0","summary":"Value stocks tend to outperform growth stocks during periods of high inflation. These companies in the Russell 1000 Value Index have high revenue growth estimates for the next two years.Microsoft is n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1712237335.SGD","LU1121112475.USD","GB00B4QBRK32.GBP","LU1551013425.SGD","LU0210533765.USD","IE00BLSP4239.USD","LU0276348264.USD","LU0823417737.USD","LU2237443895.HKD","IE00B19Z8X17.USD","LU0823417653.USD","LU2471134879.HKD","LU0068578508.USD","LU1064131342.USD","METD","LU0256863811.USD","IE0004445015.USD","IE00B1BXHZ80.USD","LU0187121727.USD","LU1670627923.USD","LU0061475181.USD","LU2357627491.SGD","IE00BWXC8680.SGD","LU2491050154.USD","LU1691799644.USD","LU0433182093.SGD","LU2271345857.HKD","SG9999014898.SGD","BK4504","LU0985320562.USD","LU0289941410.SGD","IE00B19Z3581.USD","LU0552385451.USD","LU0871640123.AUD","LU0823421416.USD","LU2461242641.AUD","LU0965509010.AUD","IE0004086264.USD","LU0312595415.SGD","LU0225283273.USD","LU2210149790.SGD","LU1046421795.USD","LU2168564495.EUR","SG9999000418.SGD","LU0689472784.USD","HK0000304797.USD","LU2023250843.SGD","IE00BJLML261.HKD","LU0820562030.AUD","LU1582986433.USD","LU0354030511.USD","IE00BYQQ9H92.USD","HK0000304805.HKD","LU1037948541.HKD","LU0238689110.USD","LU1035773651.USD","LU1506573853.SGD","LU1400636657.SGD","LU2211815571.USD","LU0788109477.HKD","LU1235295455.SGD","SG9999014906.USD","LU2360106780.USD","LU2361044865.SGD","IE0034235303.USD","LU1069344957.HKD","LU0345768153.USD","LU0738911758.USD","LU0964807845.USD","LU1803068979.SGD","LU1670711123.USD","SG9999015978.USD","LU1623119135.USD","LU1242518857.USD","IE00BZ1G4Q59.USD","LU1244550494.USD","LU0053666078.USD","LU1934455194.USD","LU2242650005.HKD","LU0642271901.SGD","LU0203345920.USD","LU1496350502.SGD","IE00BMPRXQ63.HKD","LU2065171311.SGD","IE00BQXX3C00.GBP","LU2602419157.SGD","LU2100268510.USD","LU1564329461.SGD","IE00BN8TJ469.HKD","LU1489326972.SGD","LU2063271972.USD","KKR","LU0444973449.USD","BK4581","LU1983260115.SGD","IE00B19Z9P08.USD","LU0792757196.USD","LU1989773731.SGD","IE000ITXATA3.USD","IE00BFSS7M15.SGD","LU0726765562.USD","LU1791710400.SGD","IE00BZ9MQY76.HKD","BK4567","LU0545039389.USD","LU0889566641.SGD","LU1839511570.USD","LU2264538146.SGD","LU0256863902.USD","IE00BQXX3F31.USD","LU1868836757.USD","IE00BYXW3230.USD","LU0985489474.SGD","LU0719512351.SGD","LU1400636574.HKD","LU2279689827.SGD","LU2361045086.USD","LU1699723380.USD","LU2592432038.USD","BK4548","LU2491050071.SGD","SG9999002224.SGD","LU2125909247.SGD","LU0557290698.USD","LU0345770308.USD","LU1935042991.SGD","SOFA","SG9999015952.SGD","LU1935042215.USD","LU0061474960.USD","LU2430703095.HKD","LU2322448957.HKD","IE00B5949003.HKD","LU2125154778.USD","LU1989772923.USD","LU0690374615.EUR","LU0198837287.USD","LU2471134523.USD","LU1267930730.SGD","IE00B775H168.HKD","LU0097036916.USD","IE0003U64NQ7.SGD","LU2065169927.USD","LU1340139317.AUD","LU2236285917.USD","LU0265550359.USD","LU1267930490.SGD","IE0004445239.USD","LU1188199696.SGD","IE00BKDWB100.SGD","MSFT","IE0034235295.USD","LU2108987350.USD","MSFY","BK4503","IE00BFXG0V08.USD","LU2506951958.HKD","IE00BLDYK493.USD","LU1221951129.SGD","LU1301847155.USD","LU0417517546.SGD","LU1145028129.USD","LU0138981039.USD","LU1951200564.SGD","LU1992135399.USD","IE0001KFT4U8.USD","IE00B19Z8W00.USD","LU0096364046.USD","LU1236620750.USD","IE00B3SWFQ91.USD","LU2041044095.USD","LU0823434740.USD","LU1235294995.USD","BK4524","HK0000914660.USD","LU1116320737.USD","LU0314104364.USD","IE00BBT3K403.USD","LU1221951046.USD","LU2746668974.SGD","LU0784384876.USD","LU1066051498.USD","BK4507","LU0553294199.USD","LU2087625088.SGD","LU2275660780.HKD","LU2637965513.SGD","LU0072461881.USD","CG","LU2413666426.HKD","MSFO","LU1732799900.SGD","LU1236620834.HKD","LU2237443622.USD","LU0234570918.USD","LU2023251221.USD","LU0757359368.USD","LU2756315664.SGD","IE00B19Z9Z06.USD","LU2250418816.HKD","LU0690374961.EUR","BX","LU2322448791.USD","LU2505996681.GBP","LU2272731865.HKD","IE00BJJMRY28.SGD","LU0157215616.USD","LU1202635105.USD","LU1674673428.USD","LU2463028550.USD","IE00BQXX3D17.EUR","LU0494093205.USD","LU2360108059.USD","LU1366333091.USD","IE00BJTD4N35.SGD","IE00BN29S564.USD","LU0095938881.EUR","FBYY","LU0979878070.USD","LU1880398554.USD","LU0128525929.USD","LU0345774391.USD","BK4533","BK4549","LU2097829019.USD","LU2506952170.USD","LU1668664300.SGD","LU2506952097.USD","LU0784385170.HKD","LU2860962120.EUR","LU0107464264.USD","LU2286300806.USD","LU1153585028.USD","IE00B7SZLL34.SGD","SG9999014567.USD","LU0174119429.USD","LU0069063385.USD","LU1823568750.SGD","LU1861127337.USD","LU2360032135.SGD","LU1232071149.USD","LU1032466523.USD","LU0308772762.SGD","BK4566","LU2237443978.SGD","LU2237957902.USD","LU1564329032.USD","LU0215105999.USD","LU1496350171.SGD","LU2028103732.USD","LU1951198990.SGD","LU2083900584.USD","BK4543","BK4612","BK4135","LU1880398471.USD","LU2237443465.HKD","BK4528","LU0724617625.USD","LU1935043023.USD","LU1366192091.USD","LU1645745479.HKD","LU0171293334.USD","LU1988902786.USD","LU1069347547.HKD","LU1127390331.HKD","LU1400636491.USD","LU2473716301.USD","LU1582986359.USD","IE00BKVL7J92.USD","LU1280957306.USD","LU0154236417.USD","LU1934455863.HKD","LU0672654240.SGD","LU0661504455.SGD","LU0980610538.SGD","SG9999014559.SGD","LU0390134368.USD","LU0011850046.USD","LU1003077747.HKD","LU0912757837.SGD","LU2458330169.SGD","METW","UTHR","BK4538","LU2317271919.USD","LU1116320901.HKD","LU2326559502.SGD","MSFD","LU1720051017.SGD","LU1119994496.HKD","LU0211327993.USD","LU2237443382.USD","LU2433249047.HKD","LU0708994859.HKD","SG9999015986.USD","LU1868837300.USD","LU0320765992.SGD","LU1084165304.USD","MSFL","LU2750360641.GBP","LU2506951875.HKD","LU2065170008.USD","FICO","HK0000914686.HKD","SGXZ81514606.USD","IE00B64QTZ34.USD","IE00B775SV38.USD","LU0345774631.USD","LU0466842654.USD","LU1435385759.SGD","LU0211331839.USD","LU0342679015.USD","LU2505996509.AUD","LU2720916845.USD","LU1791807156.HKD","LU2417539215.USD","LU0545562505.USD","LU1316542783.SGD","BK4592","IE00BHPRN162.USD","LU0149725797.USD","LU0476273544.USD","LU1066051225.USD","SG9999015358.SGD","LU2362541513.USD","LU0472753341.HKD","IE00B4JS1V06.HKD","LU1430594728.SGD","LU2168564149.EUR","LU2023250330.USD","LU0784383803.USD","LU0823421333.USD","MSFU","LU2089284900.SGD","BK4577","LU0894486033.HKD","LU0859254822.USD","LU0289739343.SGD","LU1815336760.USD","IE00B3QW5Z07.USD","LU2133065610.SGD","LU2420271590.USD","SG9999014880.SGD","IE00B7KXQ091.USD","SGXZ31699556.SGD","LU0289961442.SGD","LU1674673691.USD","IE00BJTD4V19.USD","LU2487616109.SGD","BK4579","BK4023","LU0795875169.SGD","IE00B64PRP62.GBP","LU1066051811.HKD","LU0124676726.USD","LU2106854487.HKD","LU2357305700.SGD","LU1267930573.SGD","TPG","LU1564329115.USD","IE0034235188.USD","LU0456855351.SGD","LU1778281490.HKD","LU2403377893.USD","LU0426412945.USD","LU1803068623.USD","LU1934455277.USD","LU2347655073.USD","LU2404859667.USD","LU1974910355.USD","LU0133085943.USD","LU0426417589.USD","IE00B5TLWC47.USD","LU0208291251.USD","LU3102509885.SGD","IE00BLSP4452.SGD","LU2347655156.SGD","LU2191332357.HKD","LU0006306889.USD","LU0894485498.HKD","SG9999015341.SGD","LU0640476718.USD","LU0960925559.SGD","LU2237438978.USD","LU2095319765.USD","BK4527","LU0323239441.USD","BK4587","LU1043141396.HKD","IE00B894F039.SGD","HK0000819398.USD","LU1670756490.USD","LU2047632596.USD","LU0072462426.USD","LU1242518931.SGD","LU0109394709.USD","LU0302445910.USD","IE000YTNTUN2.SGD","LU0162691827.USD","BK4550","SOFI","SG9999017495.SGD","LU0289960550.SGD","LU0251132253.USD","LU2125909593.SGD","IE00BDCRKT87.USD","LU0348723411.USD","BK4551","IE00BFSS8Q28.SGD","LU0787776722.HKD","LU1585245621.USD","LU0879622024.SGD","LU1868837136.USD","LU2756315318.SGD","LU1791710582.SGD","LU0158827781.USD","LU0211328371.USD","LU1633808545.USD","LU2168563687.JPY","LU1571399168.USD","LU2430703178.SGD","LU1989764664.SGD","IE0004091025.USD","LU1718418525.SGD","LU1989764748.USD","BK4139","BK4554","BK4576","LU0786609619.USD","LU0949170772.SGD","IE00B4YYXB79.USD","LU1074936037.SGD","LU1861559042.SGD","IE00B19Z9505.USD","LU0096362180.USD","LU1244550221.USD","IE00BSNM7G36.USD","LU2054465674.USD","GB00B4LPDJ14.GBP","HK0000532082.HKD","LU0957808578.USD","LU0127658192.USD","LU1629891620.HKD","BK4598","LU0353189680.USD","LU0708995401.HKD","LU0648001328.SGD","LU1721428933.USD","SGXZ23171101.USD","LU1923622614.USD","BK4532","LU0795875086.SGD","LU2097344357.USD","IE0009356076.USD","IE000W1ABFV2.USD","LU0106261372.USD","SG9999001077.SGD","LU0203202063.USD","LU0320765059.SGD","SOFX","LU0109392836.USD","LU0868494617.USD","LU0950375773.USD","HUBS","LU2458330243.SGD","LU0082616367.USD","LU1935043536.SGD","LU2462591350.SGD","LU0528227936.USD","LU0957791311.USD","LU0345770993.USD","GB00BDT5M118.USD","LU2168564065.EUR","LU1181866309.USD","LU1670628061.USD","LU2242649171.HKD","LU1992135472.HKD","IE0005OL40V9.USD","LU0081259029.USD","LU0784385840.USD","LU2272731782.SGD","LU2413666699.HKD","LU1861558580.USD","SGXZ99366536.SGD","LU1037948897.HKD","LU1201861249.SGD","LU2896262040.SGD","IE00BGHQF748.EUR","LU0316494557.USD","IE00BK4W5L77.USD","LU2272731600.USD","LU2552382058.USD","LU0109391861.USD","LU2148611432.USD","GWRE","IE00BKPKM429.USD","LU0889565833.HKD","SG9999014914.USD","IE0002270589.USD","LU1815333072.USD","LU2430703251.USD","LU0949170426.SGD","LU1732800096.USD","LU2023250504.SGD","IE00B19Z3B42.SGD","LU0094547139.USD","LU1720051108.HKD","LU2213496289.HKD","META","LU1935042488.USD","MSFW","LU1244550577.SGD","LU1670711040.USD","LU1429558221.USD","LU0266013472.USD","LU0265550946.USD","LU1989763005.USD","BK4613","LU2452424414.USD","LU1582987597.SGD","LU0310799852.SGD","LU1261432733.SGD","LU1228905540.USD","SG9999014542.SGD","LU1066053197.SGD","LU2092937148.SGD","IE00BK4W5M84.HKD","LU0234572021.USD","LU0079474960.USD","METU","SG9999018857.SGD","KVYO","LU1035775433.USD","MSFX","LU0820561818.USD","LU2077746001.SGD","LU0757359954.USD","LU2764263039.SGD","LU0345769128.USD","BK4097","BK4585","SG9999018865.SGD","LU0444971666.USD","LU0965508806.USD","LU1923623000.USD","LU1642822529.SGD","LU0861579265.USD","LU1228905037.USD","BK4516","LU0061474705.USD","LU0345769631.USD","SG9999004303.SGD","LU2361044949.HKD","LU1334329650.SGD","LU1917777945.USD","LU2092627202.USD","SG9999002232.USD","LU0070302665.USD","LU0210536198.USD","LU0203347892.USD","LU1043141123.HKD","LU1852331112.SGD","LU0203201768.USD","LU2362541273.HKD","LU1267930813.SGD","LU1548497426.USD","LU1989772840.SGD","LU2491049909.HKD","LU2244417387.USD","LU2237443549.SGD","LU2237957811.SGD","LU2092937221.SGD","BK4535","IE000KEQY171.SGD","LU2471134952.CNY","LU0882574139.USD","LU2764263203.CNY","LU0889565916.HKD","LU1670710661.SGD","LU1582987324.SGD","LU0057025933.USD","LU1564329628.SGD","ASND","LU0314106906.USD","SG9999014575.USD","LU0267386448.USD","LU2746668461.USD","LU2381873111.SGD","LU2404859741.USD","BK4525","IE00BDRTCR15.USD","LU2087621335.USD","LU2543165471.USD","FBY","LU2362540622.SGD","IE0009G5SDU7.USD","LU1868836591.USD","LU2111349929.HKD","BK4588","LU0965509283.SGD","LU1814569148.SGD","BK4077","FBL","LU2298321311.HKD","IE00BMPRXR70.SGD","LU2552382215.SGD","LU1914381329.SGD","LU2125154935.USD","BK4166","LU2456880835.USD","LU0878866978.SGD","IE00BMPRXN33.USD","LU0347712357.USD","LU1323610961.USD","LU1804176565.USD","LU0943347566.SGD","IE00BJJMRX11.SGD","LU0323240290.USD","LU0077335932.USD","LU0070217475.USD","LU0056508442.USD","LU2210150020.SGD","LU2552382132.HKD","LU2089283258.USD","BILL","LU0170899867.USD","BK4608","LU1697837992.HKD","LU2471134796.USD","LU2265009873.SGD","LU2102340556.USD","SG9999001424.SGD","IE00B3S45H60.SGD","LU1059921491.USD","LU2764262908.HKD","LU0511384066.AUD","LU2168564222.USD","LU0323591593.USD","SG9999015945.SGD","LU0080751232.USD","LU0158827948.USD","LU2462157665.USD","LU0820561909.HKD","LU1196500208.SGD","LU0310800379.SGD","LU0354030438.USD","LU0320765489.SGD","LU0048584097.USD","LU0353189763.USD","LU2750360997.AUD","SGXZ51526630.SGD","LU2065171402.SGD","LU0965509101.SGD","LU0823434583.USD","LU2247934214.USD","IE00B1XK9C88.USD","LU1670710588.SGD","LU0175139822.USD","LU1551013342.USD","LU0106831901.USD","LU0683600562.USD","LU0130102774.USD","LU0994945656.USD","LU1032955483.USD","LU2097344431.USD","LU0029864427.USD","LU0963586101.USD","LU1868836914.USD","LU0345768740.USD","LU0210528500.USD","BK4534","LU0689626769.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647559020","title":"Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647559020","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647559020?lang=en_us&edition=fundamental","pubTime":"2026-06-30 21:15","pubTimestamp":1782825335,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP in child...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-reports-new-radiographic-data-from-week-104-from-approach-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-reports-new-radiographic-data-from-week-104-from-approach-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASND","BK4139","LU0109394709.USD","LU0889565916.HKD","BK4585","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647555774","title":"Ascendis Says Transcon CNP Achondroplasia Trial Shows Continued Leg-alignment Gains at Week 104","url":"https://stock-news.laohu8.com/highlight/detail?id=2647555774","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647555774?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:32","pubTimestamp":1782822737,"startTime":"0","endTime":"0","summary":"Ascendis says TransCon CNP achondroplasia trial shows continued leg-alignment gains at Week 104Ascendis Pharma disclosed 2-year data from its completed pivotal ApproaCH trial; results were presented a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL5p7BZs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4112","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","SG9999014039.USD","IE00BN0W2T93.GBP","BK4139","SG9999014021.USD","ASND","BK4585","BK4588","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646360316","title":"Ascendis Pharma Added to Multiple Russell Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2646360316","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646360316?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:11","pubTimestamp":1782504701,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) said Friday it has been added to the Russell 3000, Russell 1000, Russell 2500 and Russell Midcap indexes as part of the 2026 Russell US Indexes semi-annual reconstitution, effective after the close of US markets on June 26.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","BK4139","BK4585","ASND","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646853713","title":"Ascendis Pharma Reports Week 104 Approach Trial Data Showing Improved Leg Alignment with Transcon CNP in Achondroplasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2646853713","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646853713?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:01","pubTimestamp":1782417693,"startTime":"0","endTime":"0","summary":"Ascendis Pharma reports Week 104 ApproaCH trial data showing improved leg alignment with TransCon CNP in achondroplasiaAscendis Pharma will present new follow-up data on its once-weekly TransCon CNP a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL6PDvD3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","IE00B64PRP62.GBP","BK4588","IE00BGHQF748.EUR","SG9999014039.USD","LU0889565916.HKD","IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU0320765992.SGD","SG9999014005.SGD","LU0109394709.USD","IE00BN0W2W23.USD","NDAQ","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","SG9999014021.USD","LU0314104364.USD","ASND","SG9999014013.SGD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124872966","title":"Movement Alert｜Ascendis Pharma Rises 8.3% in Regular Trading, Core Drug Long-Term Clinical Data Impresses as Analysts Reiterate Bullish Stance","url":"https://stock-news.laohu8.com/highlight/detail?id=1124872966","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124872966?lang=en_us&edition=fundamental","pubTime":"2026-06-26 00:16","pubTimestamp":1782404194,"startTime":"0","endTime":"0","summary":"On June 25, Ascendis Pharma rose 8.3% in regular trading, trading at approximately $259.16/share, with turnover of $327 million. The rally was driven by the market continuing to digest strong...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644031007","title":"Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Corbus Pharmaceuticals (CRBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644031007","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644031007?lang=en_us&edition=fundamental","pubTime":"2026-06-18 15:50","pubTimestamp":1781769052,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND) and Corbus Pharmaceuticals (C...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-and-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-and-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","HCSG","LU0109394709.USD","XLV","LABU","LU0128526141.USD","CRBP","LU0320765992.SGD","ASND","BK4581","BK4139","BK4585","XBI","BK4137","LU0889565916.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644210607","title":"Ascendis Pharma sells priority review voucher for $187.5 million cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2644210607","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644210607?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:48","pubTimestamp":1781729318,"startTime":"0","endTime":"0","summary":"Ascendis Pharma completed the sale of its Rare Pediatric Disease Priority Review Voucher to an undisclosed buyer for USD 187.5 million cash.Transaction closed June 17, 2026; proceeds reported before transaction-related expenses.The voucher was awarded by the FDA following the February 2026 approval of YUVIWEL .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL383ftf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND","BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644881748","title":"Ascendis Pharma (ASND) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2644881748","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644881748?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:35","pubTimestamp":1781692553,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Derek Archila maintained a Buy rating on Ascendis Pharma today and set a price target of $326.00. Archila covers the Healthcare...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU0889565916.HKD","LU2461242641.AUD","IE00B19Z3581.USD","LU0052756011.USD","LU0149725797.USD","LU1668664300.SGD","BK4504","LU0154236417.USD","LU0208291251.USD","LU1069347547.HKD","LU0029864427.USD","LU0708994859.HKD","IE000M9KFDE8.USD","IE0002270589.USD","LU0310800379.SGD","BK4581","LU2361045086.USD","LU1267930227.SGD","LU0128525689.USD","LU2236285917.USD","LU0211327993.USD","BK4582","XLV","LU0130517989.USD","LU0417517546.SGD","LU0742534661.SGD","LU1201861249.SGD","LU0072461881.USD","LU0868494617.USD","LU0683600562.USD","LU1267930573.SGD","LU0640476718.USD","LU0251142724.SGD","LU0868494708.USD","LU0310799852.SGD","PGF","BK4139","LU0971096721.USD","LU0251131958.USD","LU0942090050.USD","LU0267386448.USD","LU0162691827.USD","LU1035773651.USD","ASND","LABU","LU0289960550.SGD","LU0320765489.SGD","LU0980610538.SGD","LU0477156953.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643757879","title":"Analysts’ Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643757879","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643757879?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:40","pubTimestamp":1781613612,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-amylyx-pharmaceuticals-inc-amlx-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-amylyx-pharmaceuticals-inc-amlx-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4137","BK4581","BK4139","LU0109394709.USD","LU0128526141.USD","XLV","LU0320765992.SGD","ASND","BK4585","LABU","AMLX","HCSG","LU0889565916.HKD","BK4007","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643048092","title":"Ascendis Pharma's Yorvipath Has Superior Profile Relative to Competitors, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2643048092","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643048092?lang=en_us&edition=fundamental","pubTime":"2026-06-15 22:54","pubTimestamp":1781535244,"startTime":"0","endTime":"0","summary":"Ascendis Pharma's  Yorvipath hypoparathyroidism therapy maintains a superior clinical profile compared with competing programs, Wedbush analysts said in a Monday note.The company's 3.5-year data from the phase-3 PaTHway study and the 5-year data from the phase-2 PaTH Forward study of Yorvipath in hypoparathyroidism provide strong evidence for sustained clinical benefit from long-term treatment, analysts said.Wedbush said that both studies showed high retention rates, durable efficacy, and continued improvement in renal function with longer treatment.Quality of life improvement, which is now required by the FDA for approvals, is the strongest evidence for Yorvipath's efficacy, a key opinion leader said, according to analysts.Wedbush has an outperform rating and a $273 price target on the stock.Price: 223.74, Change: +5.68, Percent Change: +2.60","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASND","LU0320765992.SGD","LU0889565916.HKD","SPN","LU0109394709.USD","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643272180","title":"Ascendis reports sustained efficacy, safety for TransCon PTH in PaTHway hypoparathyroidism trial at Week 182","url":"https://stock-news.laohu8.com/highlight/detail?id=2643272180","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643272180?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:15","pubTimestamp":1781518506,"startTime":"0","endTime":"0","summary":"The update showed sustained long-term disease control, with most patients maintaining normal mineral balance while reducing reliance on conventional supplements.Patient-reported symptoms and quality of life remained improved over the multi-year follow-up.The safety profile stayed consistent over time, with no new safety concerns reported.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL1Df1ft:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0320765992.SGD","BK4585","BK4139","LU0109394709.USD","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643732247","title":"Ascendis Pharma completes Phase 3 PaTHway Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643732247","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643732247?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:40","pubTimestamp":1781469605,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH demonstr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-completes-phase-3-pathway-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-completes-phase-3-pathway-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0889565916.HKD","BK4585","ASND","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascendispharma.com","stockEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.2917},{"period":"3month","weight":0.1511},{"period":"6month","weight":0.3569},{"period":"1year","weight":0.5675},{"period":"ytd","weight":0.2916}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0199},{"period":"3month","weight":0.1063},{"period":"6month","weight":0.083},{"period":"1year","weight":0.2045},{"period":"ytd","weight":0.1023}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.031281},{"month":2,"riseRate":0.583333,"avgChangeRate":0.050705},{"month":3,"riseRate":0.416667,"avgChangeRate":0.030446},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.031037},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.005122},{"month":6,"riseRate":0.666667,"avgChangeRate":0.035016},{"month":7,"riseRate":0.666667,"avgChangeRate":0.003029},{"month":8,"riseRate":0.727273,"avgChangeRate":0.084941},{"month":9,"riseRate":0.636364,"avgChangeRate":0.039794},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.00981},{"month":11,"riseRate":0.818182,"avgChangeRate":0.047363},{"month":12,"riseRate":0.545455,"avgChangeRate":0.041981}],"exchange":"NASDAQ","name":"Ascendis Pharma A/S","nameEN":"Ascendis Pharma A/S","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ascendis Pharma A/S,ASND,Ascendis Pharma A/S股票,Ascendis Pharma A/S股票老虎,Ascendis Pharma A/S股票老虎国际,Ascendis Pharma A/S行情,Ascendis Pharma A/S股票行情,Ascendis Pharma A/S股价,Ascendis Pharma A/S股市,Ascendis Pharma A/S股票价格,Ascendis Pharma A/S股票交易,Ascendis Pharma A/S股票购买,Ascendis Pharma A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction